Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S. Datoo, Nsajigwa Misidai, Alassane Dicko et al.|The Lancet|2024Cited by 345
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling studyNora Schmit, Peter Winskill, Hillary M. Topazian et al.|The Lancet Infectious Diseases|2024Cited by 48
A Phase III Randomised Controlled Trial Evaluating the Malaria Vaccine Candidate R21/Matrix-M™ in African ChildrenMehreen Datoo, Adrian V. S. Hill, Alassane Dicko et al.|SSRN Electronic Journal|2023Cited by 29
Cost of introducing and delivering malaria vaccine (RTS,S/AS01<sub>E</sub>) in areas of seasonal malaria transmission, Mali and Burkina FasoHalimatou Diawara, Ranju Baral, Seydou Yabré et al.|BMJ Global Health|2023Cited by 12